4 ms·
Sounds like very low dosages; for comparison: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725 https://dom-pubs.onlinelibrary.wiley.com/doi/10.11
by petesergeant 3y ago
Sounds like very low dosages; for comparison:
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725 https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.147...
> mean weight loss was 17.3% (SD: 9.3%) with [2.4mg] semaglutide and 2.0% (SD: 6.1%) with placebo
Re financing, they’re incredibly expensive in the US, but in the UK Ozempic ends up being ~£200 a month, and many people seem to find they save that much in food costs. Also this stuff is dead easy to manufacture, every pharma company seems to have their own version in the pipeline, and some of the very first versions (eg liraglutide, from memory) aren’t too far off patent expiry.
- deprecative 3y agoI wonder if this might mean that a version 1.x or 2 is somewhere in the pipeline with (eventual) better results to some nth degree. Really hoping we can get some more of these in the US and that the prices will come down as things change.
- petesergeant 3y agoThey very much are! Retatrutide and (semaglutide + cagrilintide) and danuglipron seem to be the ones to watch